ARTICLE | Clinical News
Intradose-FU: Started Phase II trials
January 17, 1994 8:00 AM UTC
Matrix Pharmaceutical Inc. (MATX), Menlo Park, Calif. Product: Intradose-FU injectable gel containing the cancer agent fluorouracil Indication: Outpatient treatment for prostate cancer Status: Started...